SciNeuro Pharmaceuticals secured $53 million in venture funding led by ARCH and Lilly Asia to advance an asset originally from GSK into clinical studies for diabetic ocular complications and dementia indications. The round represents continued investor interest in neuroscience and repurposing prior clinical compounds. SciNeuro said the funds will support trials in an eye complication of diabetes and exploratory work in dementia. Investors view the program as a lower‑risk, de‑riskyed development path because of prior preclinical and clinical data from the compound’s earlier programs. The financing follows a trend of ARCH backing nervous‑system focused biotechs and highlights strategic follow‑on investing in translational neuroscience assets.